• Alias: GSK2110183
    • Orally bioavailable inhibitor of the serine/threonine protein kinase AKT (protein kinase B)
    • Currently no clinical trials open for cancer in the United States; previously showed efficacy in patients with MM
    • Recommended dose: 125 mg PO daily
    • Half-life: 1.7 days
    • Common side effects: Nausea, diarrhea, dyspepsia, fatigue, anorexia, GI reflux disease, neutropenia
    (Spencer et al., 2011)
    Other topics in Targeted and Immunotherapy Agents